Simona Coco

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4931458/publications.pdf

Version: 2024-02-01

102 papers	2,756 citations	201674 27 h-index	197818 49 g-index
103 all docs	103 docs citations	103 times ranked	5533 citing authors

#	Article	IF	Citations
1	Serum levels of VCAMâ€1 are associated with survival in patients treated with nivolumab for NSCLC. European Journal of Clinical Investigation, 2022, 52, e13668.	3.4	5
2	MicroRNA Alterations Induced in Human Skin by Diesel Fumes, Ozone, and UV Radiation. Journal of Personalized Medicine, 2022, 12, 176.	2.5	4
3	Targeting PIK3CA Actionable Mutations in the Circulome: A Proof of Concept in Metastatic Breast Cancer. International Journal of Molecular Sciences, 2022, 23, 6320.	4.1	4
4	NSD1 Mutations in Sotos Syndrome Induce Differential Expression of Long Noncoding RNAs, miR646 and Genes Controlling the G2/M Checkpoint. Life, 2022, 12, 988.	2.4	4
5	A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients. Cancers, 2022, 14, 3412.	3.7	4
6	Radiomic Detection of EGFR Mutations in NSCLC. Cancer Research, 2021, 81, 724-731.	0.9	57
7	Relationship between the miRNA Profiles and Oncogene Mutations in Non-Smoker Lung Cancer. Relevance for Lung Cancer Personalized Screenings and Treatments. Journal of Personalized Medicine, 2021, 11, 182.	2.5	9
8	Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 2625.	4.1	38
9	Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: focus on challenging populations. Immunotherapy, 2021, 13, 509-525.	2.0	3
10	Cancer pathways analysis and correlation with survival in patients with advanced stage non-small cell lung cancer treated with PD-1 inhibitor.. Journal of Clinical Oncology, 2021, 39, e21007-e21007.	1.6	0
11	Aquatic reservoir of Vibrio cholerae in an African Great Lake assessed by large scale plankton sampling and ultrasensitive molecular methods. ISME Communications, 2021, 1, .	4.2	4
12	Prospective Validation of the Italian Alliance Against Cancer Lung Panel in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2021, 22, e637-e641.	2.6	4
13	Identification by MicroRNA Analysis of Environmental Risk Factors Bearing Pathogenic Relevance in Non-Smoker Lung Cancer. Journal of Personalized Medicine, 2021, 11, 666.	2.5	2
14	Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade. Frontiers in Immunology, 2021, 12, 799455.	4.8	76
15	Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges. Cancers, 2020, 12, 17.	3.7	82
16	Radiation-Related Deregulation of TUBB3 and BRCA1/2 and Risk of Secondary Lung Cancer in Women With Breast Cancer. Clinical Breast Cancer, 2020, 21, 218-230.e6.	2.4	2
17	1216P A circulating exosomal miRNA-based risk score as a predictive biomarker of relapse in early stage non-small cell lung cancer. Annals of Oncology, 2020, 31, S795.	1.2	0
18	1277P An exosomal miRNA signature as predictor of benefit from immune checkpoint inhibitors in non-small cell lung cancer. Annals of Oncology, 2020, 31, S825-S826.	1.2	2

#	Article	IF	Citations
19	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. Cancers, 2020, 12, 1125.	3.7	43
20	Performance of the OncomineTM Lung cfDNA Assay for Liquid Biopsy by NGS of NSCLC Patients in Routine Laboratory Practice. Applied Sciences (Switzerland), 2020, 10, 2895.	2.5	7
21	Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer. Frontiers in Immunology, 2020, 11, 125.	4.8	53
22	Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. Journal of Oncology, 2020, 2020, 1-10.	1.3	4
23	ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium. Expert Opinion on Pharmacotherapy, 2020, 21, 679-686.	1.8	3
24	Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment. Clinical and Translational Oncology, 2020, 22, 1603-1610.	2.4	3
25	Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer. Clinical and Experimental Metastasis, 2019, 36, 449-456.	3.3	15
26	Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study. Cancer Immunology, Immunotherapy, 2019, 68, 1351-1358.	4.2	24
27	Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab. Journal of Clinical Medicine, 2019, 8, 1011.	2.4	45
28	Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. Journal of Clinical Medicine, 2019, 8, 1566.	2.4	26
29	Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Cancers, 2019, 11, 125.	3.7	11
30	Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds. Expert Opinion on Investigational Drugs, 2019, 28, 513-523.	4.1	21
31	Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients. Molecular Medicine, 2019, 25, 15.	4.4	22
32	The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients. Journal of Translational Medicine, 2019, 17, 74.	4.4	103
33	Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer. Cancers, 2019, 11, 441.	3.7	3
34	P1.04-45 Immune-Oncology Gene Expression Profiles Allow Lung Cancer Patientsâ€™ Stratification and Identification of Responders to Immunotherapy. Journal of Thoracic Oncology, 2019, 14, S458.	1.1	0
35	P2.14-02 Interim Survival Analysis of Gefitinib Plus Vinorelbine in Advanced EGFR-Mutant Non-Small Cell Lung Cancer (Genoa Trial). Journal of Thoracic Oncology, 2019, 14, S829-S830.	1.1	2
36	P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated with Nivolumab. Journal of Thoracic Oncology, 2018, 13, S730-S731.	1.1	0

#	Article	IF	Citations
37	Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 2055-2062.	1.8	27
38	P2.03-28 Whole Exome Sequencing to Discover Lung Tumor Predisposition in Women with Previous Breast Cancer. Journal of Thoracic Oncology, 2018, 13, S726-S727.	1.1	0
39	Lung cancer predisposition in women with previous breast cancer identified by whole exome sequencing. Annals of Oncology, 2018, 29, viii674.	1.2	0
40	The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 1969-1976.	1.8	24
41	Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Nonâ€“Small Cell Lung Cancer: ¹⁸F-FDG PET/CT Study. Journal of Nuclear Medicine, 2017, 58, 1764-1769.	5.0	44
42	Understanding the checkpoint blockade in lung cancer immunotherapy. Drug Discovery Today, 2017, 22, 1266-1273.	6.4	48
43	P2.01-067 The Relevance of CEA and CYFRA21-1 as Predictive Factors in Nivolumab Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology, 2017, 12, S827-S828.	1.1	3
44	Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2017, 26, 551-561.	4.1	5
45	Exosomes: a new horizon in lung cancer. Drug Discovery Today, 2017, 22, 927-936.	6.4	90
46	New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 19-33.	1.8	6
47	Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. International Journal of Molecular Sciences, 2017, 18, 1035.	4.1	39
48	Reply to the Letter to the Editor by C. Nicolazzo et al.: â€œCirculating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapyâ€• International Journal of Molecular Sciences, 2017, 18, 1309.	4.1	1
49	Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma. Oncotarget, 2017, 8, 68627-68640.	1.8	27
50	Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma. MicroRNA (Shariqah, United Arab Emirates), 2016, 5, 12-18.	1.2	15
51	Vinflunine for the treatment of non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2016, 25, 1447-1455.	4.1	3
52	Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples. BMC Cancer, 2016, 16, 692.	2.6	27
53	Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma. Medicine (United States), 2016, 95, e5447.	1.0	12
54	Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2016, 16, 1142-1154.	1.7	8

#	Article	IF	Citations
55	Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma. Journal of Thoracic Oncology, 2015, 10, e50-e52.	1.1	11
56	3123 Correlation between circulating tumor biomarkers and positronemission tomography in advanced non-small cell lung cancer. European Journal of Cancer, 2015, 51, S644.	2.8	1
57	Genome instability model of metastatic neuroblastoma tumorigenesis by a dictionary learning algorithm. BMC Medical Genomics, 2015, 8, 57.	1.5	10
58	Clinical applications of a next-generation sequencing panel in non-small cell lung cancer. Annals of Oncology, 2015, 26, vi87.	1.2	0
59	Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in <scp>NSCLC</scp> cell lines poorly responsive to reversible <scp>EGFR</scp> tyrosine kinase inhibitors. International Journal of Cancer, 2015, 137, 2947-2958.	5.1	11
60	Next Generation Sequencing in Non-Small Cell Lung Cancer: New Avenues Toward the Personalized Medicine. Current Drug Targets, 2015, 16, 47-59.	2.1	38
61	Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGMâ„¢ Platform. International Journal of Molecular Sciences, 2015, 16, 28765-28782.	4.1	35
62	Afatinib for the treatment of non-small cell lung cancer. Expert Opinion on Orphan Drugs, 2015, 3, 1357-1364.	0.8	1
63	Belagenpumatucel-L for the treatment of non-small cell lung cancer. Expert Opinion on Biological Therapy, 2015, 15, 1371-1379.	3.1	12
64	Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. Targeted Oncology, 2015, 10, 393-404.	3.6	34
65	MicroRNA prognostic signature in malignant pleural mesothelioma.. Journal of Clinical Oncology, 2015, 33, 7562-7562.	1.6	1
66	The role of circulating free DNA (cfDNA) and circulating tumor cells (CTC) in advanced non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy (CHT).. Journal of Clinical Oncology, 2015, 33, e19090-e19090.	1.6	0
67	Abstract 4008: MiRNA expression profiling reveals a prognostic signature in malignant pleural mesothelioma. , 2015, , .		0
68	Abstract 2521: In vitro and in vivo antitumor efficacy of sequentially combined vinorelbine and gefitinib in non-small cell lung cancer. , 2015, , .		0
69	CASP8 SNP D302H (rs1045485) Is Associated with Worse Survival in MYCN-Amplified Neuroblastoma Patients. PLoS ONE, 2014, 9, e114696.	2.5	15
70	A Novel Prognostic Microrna Signature in Malignant Pleural Mesothelioma. Annals of Oncology, 2014, 25, iv542.	1.2	0
71	Efficacy of motesanib diphosphate in non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 1771-1780.	1.8	0
72	Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System. Frontiers in Oncology, 2014, 4, 242.	2.8	63

#	Article	IF	Citations
73	Oral vinorelbine in the treatment of non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 1585-1599.	1.8	22
74	Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. Future Oncology, 2014, 10, 79-90.	2.4	23
75	Lack of association betweenMDM2promoter SNP309 and clinical outcome in patients with neuroblastoma. Pediatric Blood and Cancer, 2014, 61, 1867-1870.	1.5	5
76	Role of microRNAs in malignant mesothelioma. Cellular and Molecular Life Sciences, 2014, 71, 2865-2878.	5.4	31
77	Afatinib for the treatment of advanced non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2014, 15, 889-903.	1.8	21
78	Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. Expert Opinion on Biological Therapy, 2014, 14, 1007-1017.	3.1	10
79	Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer. Drug Discovery Today, 2014, 19, 1671-1676.	6.4	33
80	Pemetrexed for the treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2013, 14, 1545-1558.	1.8	24
81	Epigenetic Silencing of DKK3 in Medulloblastoma. International Journal of Molecular Sciences, 2013, 14, 7492-7505.	4.1	18
82	Abstract 5649: Investigational study of acquired resistance to the EGFR irreversible inhibitor afatinib (BIBW2992) in wild-type and EGFR-mutant NSCLC cell lines.. , 2013, , .		0
83	Identification of ALK germline mutation (3605delG) in pediatric anaplastic medulloblastoma. Journal of Human Genetics, 2012, 57, 682-684.	2.3	19
84	High Genomic Instability Predicts Survival in Metastatic High-Risk Neuroblastoma. Neoplasia, 2012, 14, 823-IN10.	5.3	48
85	Dissecting the genomic complexity underlying medulloblastoma. Nature, 2012, 488, 100-105.	27.8	765
86	Ageâ€dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma. International Journal of Cancer, 2012, 131, 1591-1600.	5.1	53
87	Genomic aberrations in normal appearing mucosa fields distal from oral potentially malignant lesions. Cellular Oncology (Dordrecht), 2012, 35, 43-52.	4.4	24
88	Abstract 1424: KCNJ2 comprises a marker of poor prognosis and a therapeutic target in non-WNT/non-SHH medulloblastoma. , 2012, , .		1
89	Loss of 10q26.1â€“q26.3 in association with 7q34â€“q36.3 gain or 17q24.3â€“q25.3 gain predict poor outcome in pediatric medulloblastoma. Cancer Letters, 2011, 308, 215-224.	7.2	3
90	Gene expression profiling identifies eleven DNA repair genes down-regulated during mouse neural crest cell migration. International Journal of Developmental Biology, 2011, 55, 65-72.	0.6	15

#	Article	IF	Citations
91	Chromosomal aberrations and aneuploidy in oral potentially malignant lesions: distinctive features for tongue. BMC Cancer, 2011, 11, 445.	2.6	23
92	Role of CXCL13-CXCR5 Crosstalk Between Malignant Neuroblastoma Cells and Schwannian Stromal Cells in Neuroblastic Tumors. Molecular Cancer Research, 2011, 9, 815-823.	3.4	29
93	Chromosome 9q and 16q Loss Identified by Genome-Wide Pooled-Analysis Are Associated with Tumor Aggressiveness in Patients with Classic Medulloblastoma. OMICS A Journal of Integrative Biology, 2011, 15, 273-280.	2.0	7
94	Transcribed-ultra conserved region expression profiling from low-input total RNA. BMC Genomics, 2010, 11, 149.	2.8	9
95	Genome and Transcriptome Analysis of Neuroblastoma Advanced Diagnosis from Innovative Therapies. Current Pharmaceutical Design, 2009, 15, 448-455.	1.9	10
96	Transcribed-ultra conserved region expression is associated with outcome in high-risk neuroblastoma. BMC Cancer, 2009, 9, 441.	2.6	95
97	Identification of low intratumoral gene expression heterogeneity in neuroblastic tumors by genomeâ€wide expression analysis and game theory. Cancer, 2008, 113, 1412-1422.	4.1	65
98	Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization. Cancer Genetics and Cytogenetics, 2007, 177, 20-29.	1.0	39
99	Oligonucleotide Array Comparative Genomic Hybridization Profiling of Neuroblastoma Tumours. Cancer Genomics and Proteomics, 2006, 3, 245-252.	2.0	1
100	Glutathione S-transferase polymorphisms and susceptibility to neuroblastoma. Pharmacogenetics and Genomics, 2005, 15, 423-426.	1.5	7
101	Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells. Journal of Pathology, 2005, 207, 346-357.	4.5	36
102	Familial neuroblastoma: a complex heritable disease. Cancer Letters, 2003, 197, 41-45.	7.2	24